Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco® + comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® + uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® + detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
The role of POLE mutation in immunotherapy 2020-06-22
POLE encodes a protein for DNA replication. This retrospective study revealed that pathogenic POLE mutations are correlated with TMB-H and associated with a better outcome of immunotherapy.
Tipifarnib shows preliminary activities in HRAS-mutant head and neck cancer and urothelial cancer 2020-06-22
In two phase II studies published at the 2020 ASCO Virtual Scientific Program, tipifarnib demonstrated potential anti-tumor effect in head and neck cancer or urothelial cancer patients. All the recruited patients had an HRAS mutation.
Trastuzumab deruxtecan demonstrates clinical activity in HER2-mutated NSCLC 2020-06-22
According to data reported during the 2020 ASCO Virtual Scientific Meeting, trastuzumab deruxtecan showed promising activity with a high response rate and durable responses among NSCLC patients with HER2 mutation.
The current molecular biomarkers for treatment selection in NSCLC clinical practice 2020-05-22
Molecular biomarkers play an important role in NSCLC disease management. There are 11 biomarkers listed in version 4.2020 of the NCCN guideline for NSCLC, including 8 FDA-approved biomarkers and 3 emerging biomarkers for novel therapies. These biomarkers
Onvansertib regimen demonstrates anti-tumor activity in patients with metastatic KRAS-mutant CRC 2020-05-22
There is an unmet need for treating the CRC patient who has a KRAS mutation. In a phase 1b/2 study, the combination of onvansertib, FOLFIRI, and bevacizumab as second-line treatment demonstrated significant clinical benefit in KRAS-mutant CRC.
RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib demonstrates clinical activity among KRAS-mutant cancer patients 2020-05-22
Currently, there is no approved KRAS targeted therapy, and it remains challenging to treat patients who harbor KRAS mutations. According to preliminary results form an ongoing phase 1 trial, defactinib plus RAF/MEK inhibitor is active in KRAS-mutant cance
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
